DarioHealth (NASDAQ:DRIO) Posts Quarterly Earnings Results, Beats Expectations By $2.73 EPS

DarioHealth (NASDAQ:DRIO) announced its earnings results on Wednesday. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($1.48) by $2.73, FiscalAI reports. DarioHealth had a negative net margin of 186.57% and a negative return on equity of 59.48%. The business had revenue of $5.58 million for the quarter, compared to the consensus estimate of $5.46 million.

Here are the key takeaways from DarioHealth’s conference call:

• Revenue rose sequentially for a second straight quarter to $5.6 million in Q1 2026, while gross margin improved to 57% and operating expenses fell 21% year over year, showing progress toward better operating leverage.
• Management said the company added a largest-ever new channel partner in contracting stage, potentially reaching about 65 million additional covered lives and lifting total distribution reach to more than 175 million covered lives.
• The company reported a $127 million commercial pipeline across 241 opportunities and said the accounts signed in 2025 are moving through implementation, with revenue contribution expected mainly in the second half of 2026.
• DarioHealth is expanding closer to care delivery through partnerships with clinical and provider-enabled organizations, aiming to support outcomes-based and claims-based revenue models rather than relying only on digital engagement fees.
• The company highlighted early results from DarioIQ, saying AI-driven engagement programs have delivered up to 40% better retention and up to 55% higher active sessions versus control groups, which management believes strengthens its data moat.

DarioHealth Stock Down 6.7%

Shares of NASDAQ:DRIO traded down $0.58 during trading on Wednesday, reaching $8.10. The stock had a trading volume of 8,790 shares, compared to its average volume of 14,314. DarioHealth has a one year low of $5.93 and a one year high of $17.74. The company has a market capitalization of $59.13 million, a P/E ratio of -0.78 and a beta of 1.09. The company has a current ratio of 3.76, a quick ratio of 3.30 and a debt-to-equity ratio of 0.45. The firm’s 50-day simple moving average is $8.12 and its 200 day simple moving average is $10.62.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wall Street Zen downgraded shares of DarioHealth from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Stifel Nicolaus dropped their target price on shares of DarioHealth from $16.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, March 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.00.

Institutional Trading of DarioHealth

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd boosted its holdings in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after buying an additional 43,513 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of DarioHealth in the 4th quarter valued at about $35,000. 33.39% of the stock is currently owned by institutional investors.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.